Mr DABT - Vigil Neuroscience Senior Development
| VIGL Stock | USD 2.30 0.10 4.55% |
Executive
Mr DABT is Senior Development of Vigil Neuroscience
| Age | 51 |
| Address | 100 Forge Road, Watertown, MA, United States, 02472 |
| Phone | 857 254 4445 |
| Web | https://www.vigilneuro.com |
Vigil Neuroscience Management Efficiency
The company has return on total asset (ROA) of (0.3966) % which means that it has lost $0.3966 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7012) %, meaning that it created substantial loss on money invested by shareholders. Vigil Neuroscience's management efficiency ratios could be used to measure how well Vigil Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.62. The value of Return On Capital Employed is expected to slide to -0.72. At this time, Vigil Neuroscience's Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 19.9 M this year, although the value of Other Current Assets will most likely fall to about 2.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Helen MD | Enliven Therapeutics | 61 | |
| Dr Esq | Enliven Therapeutics | 47 | |
| Lucinda Warren | Cue Biopharma | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Brendan Eckelman | Inhibrx | 45 | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Matteo MD | Cue Biopharma | 55 | |
| David MBA | Inhibrx | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Anne DVM | Molecular Partners AG | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Ashraf Amanullah | Inhibrx | 56 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Bonne MBA | Inhibrx | 47 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Charbel PharmD | Inhibrx | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
Management Performance
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.4 |
Vigil Neuroscience Leadership Team
Elected by the shareholders, the Vigil Neuroscience's board of directors comprises two types of representatives: Vigil Neuroscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vigil. The board's role is to monitor Vigil Neuroscience's management team and ensure that shareholders' interests are well served. Vigil Neuroscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vigil Neuroscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Spyridon MD, Chief Officer | ||
| Weeteck Yeo, Senior Operations | ||
| Jessica PMP, Senior Management | ||
| Mr DABT, Senior Development | ||
| Christopher JD, General Secretary | ||
| Ivana JD, CEO President | ||
| Park CPA, Accounting Manager | ||
| Jennifer CPA, Chief Officer | ||
| Sharon Morani, Director Operations | ||
| Kelly Neelon, Vice Operations | ||
| M MBA, VP Development | ||
| Charles Maggs, Head FPA | ||
| Eric Brophy, Senior Technology | ||
| Sarah Carmody, VP Communications | ||
| David Gray, Chief Officer | ||
| Leah Gibson, Vice Communications | ||
| Christian Mirescu, Senior Neuroimmunology |
Vigil Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vigil Neuroscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | (4.07 M) | ||||
| Shares Outstanding | 40.88 M | ||||
| Shares Owned By Insiders | 21.27 % | ||||
| Shares Owned By Institutions | 80.15 % | ||||
| Number Of Shares Shorted | 736.69 K | ||||
| Price To Book | 1.06 X | ||||
| EBITDA | (88.47 M) | ||||
| Net Income | (82.64 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Vigil Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Return On Assets (0.40) | Return On Equity (0.70) |
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.